CGIX - Cancer Genetics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2160
+0.0019 (+0.89%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.2141
Open0.2248
Bid0.000 x 100
Ask0.830 x 3500
Day's Range0.2150 - 0.2292
52 Week Range0.2000 - 2.2500
Volume246,780
Avg. Volume206,726
Market Cap5.993M
Beta (3Y Monthly)2.66
PE Ratio (TTM)N/A
EPS (TTM)-0.943
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Benzinga19 days ago

    The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...

  • Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks20 days ago

    Cancer Genetics (CGIX) Reports Q3 Loss, Lags Revenue Estimates

    Cancer Genetics (CGIX) delivered earnings and revenue surprises of -43.75% and -26.58%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press21 days ago

    Cancer Genetics: 3Q Earnings Snapshot

    On a per-share basis, the Rutherford, New Jersey-based company said it had a loss of 31 cents. Losses, adjusted for restructuring costs and costs related to mergers and acquisitions, came to 23 cents per ...

  • GlobeNewswire21 days ago

    Cancer Genetics Reports Third Quarter 2018 Financial Results and Provides Strategic Business Updates

    RUTHERFORD, N.J., Nov. 19, 2018 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular.

  • GlobeNewswire26 days ago

    Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief Financial Officer, effective November 26, 2018. Additionally, Mr. Igor Gitelman, Chief Accounting Officer of the Company will be departing Cancer Genetics to pursue other opportunities. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “Glenn joins Cancer Genetics with a wealth of financial and accounting leadership experience, which we believe will be instrumental as we continue executing on our 2018 transformation strategy and build a foundation for sustainable growth and profitability.

  • Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know
    Zackslast month

    Will Cancer Genetics (CGIX) Report Negative Earnings Next Week? What You Should Know

    Cancer Genetics (CGIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Cancer Genetics Issues Letter to Shareholders

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders from its Chief Executive Officer Jay Roberts. Since I took on the role as Chief Executive Officer of the Company back in February 2018, we have made several positive advances in execution of our planned strategic direction in terms of our business and operations.

  • GlobeNewswire2 months ago

    Cancer Genetics and Cellaria Partner on Precision Medicine Tools

    Cancer Genetics (CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, and Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models, today announced a new collaboration to develop extensive precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics will deploy its Genomics Center of Excellence to characterize Cellaria’s pipeline of commercial and custom-developed biopharma products. Cancer Genetics will leverage its biomarker and genomics testing capabilities to better understand patient diversity across clinical disease categories.

  • Business Wire2 months ago

    Robbins Arroyo LLP: Cancer Genetics, Inc. (CGIX) Sued by Shareholders in Recently Filed Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (CGIX) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 23, 2017 and April 2, 2018. Cancer Genetics, develops, commercializes, and provides molecular and biomarker-based tests and services in the U.S., Europe, and Asia.

  • GlobeNewswire2 months ago

    Cancer Genetics Enters Supply Agreement with Agilent Technologies

    RUTHERFORD, N.J., Sept. 25, 2018 -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and.

  • PR Newswire3 months ago

    Chardan Advises NovellusDX in Cross-Border Biotech Merger

    NEW YORK , Sept. 18, 2018 /PRNewswire/ -- Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDX, Ltd., a leader in functional genomics, for ...

  • GlobeNewswire3 months ago

    Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

    Cancer Genetics, Inc. (CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional genomics, today announced the signing of a definitive agreement under which NovellusDx will merge with a newly formed Israeli subsidiary of Cancer Genetics and shareholders of NovellusDx will receive stock equal to approximately 49% of the equity of Cancer Genetics on a fully diluted basis (with certain adjustments). Cancer Genetics will be the surviving entity and expects to remain listed on the Nasdaq Stock Market. This transaction will combine Cancer Genetics’ scale, expansive test portfolio and broad data set related to tumor biology, cultivated over more than a decade, with NovellusDx’s proprietary technology and machine learning capabilities to form a leading, oncology-focused precision medicine company.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CGIX earnings conference call or presentation 14-Aug-18 12:30pm GMT

    Q2 2018 Cancer Genetics Inc Earnings Call

  • Associated Press4 months ago

    Cancer Genetics: 2Q Earnings Snapshot

    The Rutherford, New Jersey-based company said it had a loss of 13 cents per share. The diagnostics company posted revenue of $7 million in the period. The company's shares closed at 98 cents. A year ago, ...

  • ACCESSWIRE4 months ago

    Cancer Genetics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Cancer Genetics, Inc. (NASDAQ: CGIX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern ...

  • Benzinga4 months ago

    Cancer Genetics Q2 Earnings Preview

    On Tuesday, Cancer Genetics (NASDAQ: CGIX ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Wall Street analysts ...

  • ACCESSWIRE5 months ago

    Free Research Reports on DexCom and Three More Medical Research Stocks

    Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of CGIX earnings conference call or presentation 15-May-18 12:30pm GMT

    Q1 2018 Cancer Genetics Inc Earnings Call